登录
 机构网站
  1. 首页
  2. 情报产品
  3. 快讯详情

《Science，2月5日，Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection》

  • 来源专题：COVID-19科研动态监测
  • 编译者： zhangmin
  • 发布时间：2021-02-25

  • RESEARCH ARTICLE
    Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection
    View ORCID ProfileJennifer M. Dan1,2,*, View ORCID ProfileJose Mateus1,*, View ORCID ProfileYu Kato1,*, View ORCID ProfileKathryn M. Hastie1, View ORCID ProfileEsther Dawen Yu1, Caterina E. Faliti1,...

    Structured Abstract
    INTRODUCTION
    Immunological memory is the basis for durable protective immunity after infections or vaccinations. Duration of immunological memory after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and COVID-19 is unclear. Immunological memory can consist of memory B cells, antibodies, memory CD4+ T cells, and/or memory CD8+ T cells. Knowledge of the kinetics and interrelationships among those four types of memory in humans is limited. Understanding immune memory to SARS-CoV-2 has implications for understanding protective immunity against COVID-19 and assessing the likely future course of the COVID-19 pandemic.

    RATIONALE
    Assessing virus-specific immune memory over at least a 6-month period is likely necessary to ascertain the durability of immune memory to SARS-CoV-2. Given the evidence that antibodies, CD4+ T cells, and CD8+ T cells can all participate in protective immunity to SARS-CoV-2, we measured antigen-specific antibodies, memory B cells, CD4+ T cells, and CD8+ T cells in the blood from subjects who recovered from COVID-19, up to 8 months after infection.

  • 原文来源：https://science.sciencemag.org/content/371/6529/eabf4063
23浏览量
原文链接
相关报告

  • 《Science，5月20日，SARS-CoV-2 infection protects against rechallenge in rhesus macaques》
    • 来源专题：COVID-19科研动态监测
    • 编译者：xuwenwhlib
    • 发布时间：2020-05-21
    • SARS-CoV-2 infection protects against rechallenge in rhesus macaques View ORCID ProfileAbishek Chandrashekar1,*, View ORCID ProfileJinyan Liu1,*, View ORCID ProfileAmanda J. Martinot1,2,*, View ORCID ProfileKatherine McMahan1,*, View ORCID ProfileNoe B. Mercado1,*, View ORCID ProfileLauren Peter1,*, View ORCID ProfileLisa H. Tostanoski1,*, View ORCID ProfileJingyou Yu1,*, View ORCID ProfileZoltan Maliga3, Michael Nekorchuk4, View ORCID ProfileKathleen Busman-Sahay4, View ORCID ProfileMargaret Terry4, View ORCID ProfileLinda M. Wrijil2, View ORCID ProfileSarah Ducat2, David R. Martinez5, View ORCID ProfileCaroline Atyeo3,6, View ORCID ProfileStephanie Fischinger6, View ORCID ProfileJohn S. Burke6, View ORCID ProfileMatthew D. Slein6, View ORCID ProfileLaurent Pessaint7, View ORCID ProfileAlex Van Ry7, View ORCID ProfileJack Greenhouse7, View ORCID ProfileTammy Taylor7, View ORCID ProfileKelvin Blade7, Anthony Cook7, View ORCID ProfileBrad Finneyfrock7, Renita Brown7, Elyse Teow7, Jason Velasco7, View ORCID ProfileRoland Zahn8, View ORCID ProfileFrank Wegmann8, View ORCID ProfilePeter Abbink1, View ORCID ProfileEsther A. Bondzie1, View ORCID ProfileGabriel Dagotto1,3, View ORCID ProfileMakda S. Gebre1,3, Xuan He1, View ORCID ProfileCatherine Jacob-Dolan1,3, View ORCID ProfileNicole Kordana1, Zhenfeng Li1, View ORCID ProfileMichelle A. Lifton1, View ORCID ProfileShant H. Mahrokhian1, View ORCID ProfileLori F. Maxfield1, View ORCID ProfileRamya Nityanandam1, View ORCID ProfileJoseph P. Nkolola1, View ORCID ProfileAaron G. Schmidt6,9, View ORCID ProfileAndrew D. Miller10, View ORCID ProfileRalph S. Baric5, View ORCID ProfileGalit Alter6,9, View ORCID ProfilePeter K. Sorger3, View ORCID ProfileJacob D. Estes4, View ORCID ProfileHanne Andersen7, View ORCID ProfileMark G. Lewis7, View ORCID ProfileDan H. Barouch1,6,9,† See all authors and affiliations Science 20 May 2020: eabc4776 DOI: 10.1126/science.abc4776 Abstract An understanding of protective immunity to SARS-CoV-2 is critical for vaccine and public health strategies aimed at ending the global COVID-19 pandemic. A key unanswered question is whether infection with SARS-CoV-2 results in protective immunity against re-exposure. We developed a rhesus macaque model of SARS-CoV-2 infection and observed that macaques had high viral loads in the upper and lower respiratory tract, humoral and cellular immune responses, and pathologic evidence of viral pneumonia. Following initial viral clearance, animals were rechallenged with SARS-CoV-2 and showed 5 log10 reductions in median viral loads in bronchoalveolar lavage and nasal mucosa compared with primary infection. Anamnestic immune responses following rechallenge suggested that protection was mediated by immunologic control. These data show that SARS-CoV-2 infection induced protective immunity against re-exposure in nonhuman primates.
    133浏览量
    原文链接

  • 《Science，12月4日，Robust neutralizing antibodies to SARS-CoV-2 infection persist for months》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-12-22
    • Robust neutralizing antibodies to SARS-CoV-2 infection persist for months View ORCID ProfileAnia Wajnberg1,*, View ORCID ProfileFatima Amanat2,3, Adolfo Firpo4, View ORCID ProfileDeena R. Altman5, Mark J. Bailey1, View ORCID ProfileMayce Mansour1,... Science  04 Dec 2020: Vol. 370, Issue 6521, pp. 1227-1230 DOI: 10.1126/science.abd7728 Abstract Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a global pandemic with millions infected and more than 1 million fatalities. Questions regarding the robustness, functionality, and longevity of the antibody response to the virus remain unanswered. Here, on the basis of a dataset of 30,082 individuals screened at Mount Sinai Health System in New York City, we report that the vast majority of infected individuals with mild-to-moderate COVID-19 experience robust immunoglobulin G antibody responses against the viral spike protein. We also show that titers are relatively stable for at least a period of about 5 months and that anti-spike binding titers significantly correlate with neutralization of authentic SARS-CoV-2. Our data suggest that more than 90% of seroconverters make detectable neutralizing antibody responses. These titers remain relatively stable for several months after infection.
    33浏览量
    原文链接